Abstract
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].
MeSH terms
-
Animals
-
Anti-Anxiety Agents / metabolism
-
Anti-Anxiety Agents / pharmacology
-
Anti-Anxiety Agents / therapeutic use*
-
Anxiety / drug therapy*
-
Benzopyrans / metabolism
-
Benzopyrans / pharmacology
-
Benzopyrans / therapeutic use*
-
Drugs, Investigational / metabolism
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Migraine Disorders / drug therapy
-
Patents as Topic
-
Serotonin Antagonists / metabolism
-
Serotonin Antagonists / pharmacology
-
Serotonin Antagonists / therapeutic use*
-
Structure-Activity Relationship
Substances
-
Anti-Anxiety Agents
-
Benzopyrans
-
Drugs, Investigational
-
Serotonin Antagonists
-
robalzotan